IBDEI04W ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2027,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2027,1,4,0)
 ;;=4^V16.0
 ;;^UTILITY(U,$J,358.3,2027,1,5,0)
 ;;=5^FAMILY HX-GI MALIGNANCY
 ;;^UTILITY(U,$J,358.3,2027,2)
 ;;=^295292
 ;;^UTILITY(U,$J,358.3,2028,0)
 ;;=V16.1^^21^191^14
 ;;^UTILITY(U,$J,358.3,2028,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2028,1,4,0)
 ;;=4^V16.1
 ;;^UTILITY(U,$J,358.3,2028,1,5,0)
 ;;=5^FM HX-TRACH/BRONCHOG MAL
 ;;^UTILITY(U,$J,358.3,2028,2)
 ;;=^295293
 ;;^UTILITY(U,$J,358.3,2029,0)
 ;;=V16.2^^21^191^6
 ;;^UTILITY(U,$J,358.3,2029,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2029,1,4,0)
 ;;=4^V16.2
 ;;^UTILITY(U,$J,358.3,2029,1,5,0)
 ;;=5^FAM HX-INTRATHORACIC MAL
 ;;^UTILITY(U,$J,358.3,2029,2)
 ;;=^295294
 ;;^UTILITY(U,$J,358.3,2030,0)
 ;;=V16.3^^21^191^10
 ;;^UTILITY(U,$J,358.3,2030,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2030,1,4,0)
 ;;=4^V16.3
 ;;^UTILITY(U,$J,358.3,2030,1,5,0)
 ;;=5^FAMILY HX-BREAST MALIG
 ;;^UTILITY(U,$J,358.3,2030,2)
 ;;=^295295
 ;;^UTILITY(U,$J,358.3,2031,0)
 ;;=V16.40^^21^191^1
 ;;^UTILITY(U,$J,358.3,2031,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2031,1,4,0)
 ;;=4^V16.40
 ;;^UTILITY(U,$J,358.3,2031,1,5,0)
 ;;=5^FAM HX MALIG NEOPL,GENITAL
 ;;^UTILITY(U,$J,358.3,2031,2)
 ;;=^295296
 ;;^UTILITY(U,$J,358.3,2032,0)
 ;;=V16.41^^21^191^2
 ;;^UTILITY(U,$J,358.3,2032,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2032,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,2032,1,5,0)
 ;;=5^FAM HX, MALIG NEOPL OF OVARY
 ;;^UTILITY(U,$J,358.3,2032,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,2033,0)
 ;;=V16.42^^21^191^3
 ;;^UTILITY(U,$J,358.3,2033,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2033,1,4,0)
 ;;=4^V16.42
 ;;^UTILITY(U,$J,358.3,2033,1,5,0)
 ;;=5^FAM HX, MALIG NEOPL OF PROST
 ;;^UTILITY(U,$J,358.3,2033,2)
 ;;=^317952
 ;;^UTILITY(U,$J,358.3,2034,0)
 ;;=V16.43^^21^191^4
 ;;^UTILITY(U,$J,358.3,2034,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2034,1,4,0)
 ;;=4^V16.43
 ;;^UTILITY(U,$J,358.3,2034,1,5,0)
 ;;=5^FAM HX, MALIG NEOPL OF TESTIS
 ;;^UTILITY(U,$J,358.3,2034,2)
 ;;=^317953
 ;;^UTILITY(U,$J,358.3,2035,0)
 ;;=V16.49^^21^191^5
 ;;^UTILITY(U,$J,358.3,2035,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2035,1,4,0)
 ;;=4^V16.49
 ;;^UTILITY(U,$J,358.3,2035,1,5,0)
 ;;=5^FAM HX, OF OTH MALIG NEOPL
 ;;^UTILITY(U,$J,358.3,2035,2)
 ;;=^317954
 ;;^UTILITY(U,$J,358.3,2036,0)
 ;;=V16.51^^21^191^8
 ;;^UTILITY(U,$J,358.3,2036,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2036,1,4,0)
 ;;=4^V16.51
 ;;^UTILITY(U,$J,358.3,2036,1,5,0)
 ;;=5^FAM.HX-MAL. NEOP. KIDNEY
 ;;^UTILITY(U,$J,358.3,2036,2)
 ;;=^321159
 ;;^UTILITY(U,$J,358.3,2037,0)
 ;;=V16.59^^21^191^9
 ;;^UTILITY(U,$J,358.3,2037,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2037,1,4,0)
 ;;=4^V16.59
 ;;^UTILITY(U,$J,358.3,2037,1,5,0)
 ;;=5^FAM.HX-MAL. NEOP. OTH URIN
 ;;^UTILITY(U,$J,358.3,2037,2)
 ;;=^321503
 ;;^UTILITY(U,$J,358.3,2038,0)
 ;;=V16.6^^21^191^12
 ;;^UTILITY(U,$J,358.3,2038,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2038,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,2038,1,5,0)
 ;;=5^FAMILY HX-LEUKEMIA
 ;;^UTILITY(U,$J,358.3,2038,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,2039,0)
 ;;=V16.7^^21^191^7
 ;;^UTILITY(U,$J,358.3,2039,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2039,1,4,0)
 ;;=4^V16.7
 ;;^UTILITY(U,$J,358.3,2039,1,5,0)
 ;;=5^FAM HX-LYMPH NEOPLAS NEC
 ;;^UTILITY(U,$J,358.3,2039,2)
 ;;=^295299
 ;;^UTILITY(U,$J,358.3,2040,0)
 ;;=V16.8^^21^191^13
 ;;^UTILITY(U,$J,358.3,2040,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,2040,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,2040,1,5,0)
 ;;=5^FAMILY HX-MALIGNANCY NEC
 ;;^UTILITY(U,$J,358.3,2040,2)
 ;;=^295300
